NVO: 6-K company filing

6-K 1 f6k_101926.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 19, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd , Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12 -month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 12 October, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 23,090,000 6,758,876,433 12 October 2026 250 ,0 00 257.4 1 64 ,351,856 13 October 2026 245,000 258.17 63,251,159 14 October 2026 245,000 254 .86 62,44 1,0 19 15 October 2026 245,000 259.36 63,54 3,4 0 5 16 October 2026 240 ,0 00 260 .67 62,560 ,442 Accumulated under the programme 24,315,000 7,075,024,314 Th